{"prompt": "['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', 'peer-reviewed journals. Researchers will be able to locate and access data and/or other specimens from', 'the VWDMin Trial by formal application which can be found on the BioLINCC website,', 'https://biolincc.nhlbi.nih.gov This repository has data access policies and procedures in place that will', 'provide data access to qualified researchers, consistent with NIH data sharing policies and applicable laws', 'and regulations. Once an investigator application request is approved by NHLBI, and upon receipt of a', 'Research Materials Distribution Agreement, data will be transferred by secure transfers through the', 'BioLINCC website. For biologic specimen requests, upon NHLBI approval of an investigator application', 'request, and with evidence of funding and adequate facilities and expertise to perform the proposed', 'research, BioLINCC will request that the repository prepare and ship the requested biologic specimens.', 'In addition, this study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-', 'funded research that generates large-scale human or non-human genomic data, as well as the use of these', 'data for subsequent research. Large-scale data include genome-wide association studies (GWAS), single', 'nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and gene', 'expression data.', '10.1.11', 'CONFLICT OF INTEREST POLICY', 'The independence of this study from any actual or perceived influence, such as by the pharmaceutical', 'industry, is critical. Therefore, any actual conflict of interest of persons who have a role in the design,', 'conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore,', 'persons who have a perceived conflict of interest will be required to have such conflicts managed in a way', 'that is appropriate to their participation in the design and conduct of this trial. The study leadership in', 'conjunction with NHLBI has established policies and procedures for all study group members to disclose', 'all conflicts of interest and will establish a mechanism for the management of all reported dualities of', 'interest.', '10.2 ADDITIONAL CONSIDERATIONS', '10.2.1 COSTS AND PAYMENTS', 'Research Study Costs. No costs will be incurred by the subject for their participation in this study for', 'research procedures. NIH will compensate HTCs for research procedures as outlined in the contract and', 'budget. IRB preparation costs will be covered, along with research procedures, including screening visits,', 'blood draws for local and central laboratories, blood processing, shipping, lab assays, and HTC charges', 'and services related this study protocol. Pending notification of funding, an NIH-contracted pharmacy', 'will provide rVWF and TA for administration in this study. Research blood draw kits will be prepared by', 'the CRHC DC, according to the linked randomization allocation codes for each study subject, and', 'shipped to each HTC for enrolled subjects.', 'Research Study Payments. Subjects will receive compensation for participation in this study, to help', 'defray the cost of meals, travel, and time lost from work. There will be no additional costs to study', 'subjects for participation in this study beyond the charges for routine medical care and administration of', '47']['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', 'medications. The study is pending funding by NHLBI. Compensation is based on visits and frequency of', 'blood draws. Subjects will receive $100 per visit for up to 4 visits during the 24-week trial, including', 'screening visit and 3 study visits, the latter of which includes the end-of-study visit. If subjects do not', 'complete any part of the scheduled study days, compensation for missed visits will not be made. A', 'check will be mailed to each subject upon completion of the study, at least within 4-6 weeks of end of', 'study. If, for whatever reason, subjects complete part but not all of the study, the terms of payment will', 'be determined by the number of visits completed.', '10.2.2 HUMAN SUBJECTS', 'General Characteristics - Minority Inclusion and Non-Discriminatory Statements. Adult females age 18-', '45 years of age with type 1 von Willebrand disease, defined by VWF:RCo <0.50 IU/ml (historic or current),', 'normal VWF multimers, previous bleeding history, and who have menorrhagia and a PBAC >100 in at least', 'one of the two preceding menstrual cycles, and cared for at one of the 19 or more participating centers', 'participating in this trial will be eligible for study. It is estimated that up to 60 eligible subjects (inflated to', '66 to anticipate dropout). will be enrolled (Table 1). Children will be excluded as most have not reached', 'menarche, and the safety of rVWF in children has not been established in children. We shall attempt to', 'recruit subjects in respective proportion to these demographics. All subjects will be screened prior to', 'enrollment for history and laboratory data confirming a VWD diagnosis. Written informed consent will be', 'obtained from all subjects at the screening visit. Once eligibility is confirmed, visit 1 will be defined as start', 'of enrollment. It is estimated that the HCWP site will screen and enroll 2-5 subjects locally, and up to 60', '(inflated to 66 to anticipate dropout) nationally. The requirement for PBAC >100 based in at least one of', 'the two preceding menstrual cycles will also serve as baseline menstrual severity for comparison with', 'study drugs.', 'Inclusion of Children. As this study concerns menstrual cycle bleeding, only adult women, 18-45 years of', 'age will be included. Children are excluded from participation as most have not reached menarche, and', 'the safety of rVWF in children has not been established.', '10.2.3 QUALIFICATIONS', 'Qualifications of Investigators. Dr. Margaret Ragni is a Professor of Medicine, Division', 'Hematology/Oncology, and Director of the Hemophilia Center of Western PA, and has conducted', 'numerous clinical research studies at the University, investigator-initiated and in collaboration with the', 'CDC, FDA, NIH, pharmaceuticals. She is an expert in the area of von Willebrand disease, including', 'pioneer studies of new agents, including rVWF in clinical trials, multicenter genotype phenotype VWD', 'studies, development of better predictors of VWD in children, and developing better therapies for', 'menorrhagia in women with VWD.', 'Dr. Craig Seaman is an Assistant Professor of Medicine, Division Hematology/Oncology, and Assistant', 'Director of the Hemophilia Center of Western PA. He collaborates with Dr. Ragni on clinical research', 'studies, and is focusing on investigator-initiated studies in hypertension and cardiovascular disease in von', 'Willebrand disease.', '48']\n\n###\n\n", "completion": "END"}